继发于放化疗的再生障碍性贫血:免疫抑制治疗的有效性
该研究回顾了2559例再生障碍性贫血(AA)患者中43例继发于放化疗者,其中18例接受免疫抑制治疗(IST),50%获得改善;
要点
- 继发于放化疗的AA患者,IST治疗可使50%改善,且不受GPI(-)细胞影响。
核心结论
- 对继发于放化疗的AA患者,尤其原发实体瘤处于完全缓解(CR)时,应考虑免疫抑制治疗(IST)。
研究设计与样本
- 回顾性分析2559例AA患者中43例继发于放化疗者,其中实体瘤25例、血液肿瘤18例。
- 18例接受IST治疗,其余未治疗。
主要发现
- 接受IST的18例中50%改善,改善与否与GPI(-)细胞存在无关。
- 4例非CR状态接受IST者中2例出现癌症加重。
- 2例无GPI(-)细胞患者进展为骨髓增生异常综合征(MDS)。
临床怎么用
- 继发于放化疗的AA患者,尤其原发实体瘤处于CR时,可考虑IST治疗。
- IST前需评估原发癌症状态,非CR者需警惕癌症加重风险。
局限性
- 样本量小(43例),IST组仅18例。
- 回顾性研究设计,可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The outcome of immunosuppressive therapy (IST) and prognosis in patients with aplastic anaemia (AA) secondary to chemotherapy or radiotherapy for cancers remains unknown. A total of 43 of 2559 patients with AA referred to our hospital had previously received chemoradiotherapy for various types of solid tumours (n = 25) or haematological malignancies (n = 18). Their cancer status was complete remission (CR) in 27, non-CR in 13, and unknown in three. Small populations of glycosylphosphatidylinositol-anchored protein-deficient [GPI(-)] granulocytes were detected in 16 patients (37·2%). Of 18 patients who were treated with IST, 50% improved regardless of the presence of GPI(-) cells. The overall survival (OS) rate was significantly higher in patients with a history of solid tumours patients than in those of haematological malignancies (median OS, 87 vs. 11 months, P = 0·0003), and in patients treated with IST than in those of untreated patients (median OS, 115 vs. 20 months, P = 0·028). Cancer aggravation occurred in two of four patients who were treated with IST while in non-CR of their original cancers. Progression to myelodysplastic syndromes was observed in two patients not possessing GPI(-) cells. IST should thus be considered for patients with AA secondary to chemoradiotherapy for cancers, particularly when their original solid tumours are in CR.
引用
- Nakagawa N, Ishiyama K, Tanabe M, et al. The effectiveness of immunosuppressive therapy in patients with aplastic anaemia secondary to chemoradiotherapy for cancers. Br J Haematol. 2021. PMID: 34476805. doi:10.1111/bjh.17802
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。